Johnson & Johnson JNJ

$276.22 +3.90 (1.43%)

Valuation

Market cap
664,947,200,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
P/E (trailing)
25.57
P/E (forward)
24.50
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
8,861,000
Avg volume
7,213,330
Day's range
$265.55 – $276.41
Shares out
2,407,310,000
Stochastic %K
67%
Beta
0.22
Analysts
Moderate Buy
Price target
$281.64

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

theoptionsplug Nov 9, 1:43 PM
What a bounce for $JNJ off the 50DMA! Back in the ~$280 resistance area - will there be enough juice to break through?! Yesterday, $JNJ disclosed new patient experience insights from its Phase 2 DAHLIAS trial evaluating nipocalimab for Sjögren’s disease!
0 replies
EarlyBirdEmail Nov 9, 11:45 AM
$NVDA $ETH $JNJ Nvidia CEO Jensen Huang admitted to having a romantic relationship with someone the media reported to be a Chinese Spy, prompting a new investigation on Sunday. https://www.earlybird.email/p/nvidia-ceo-jensen-huang-admits-affair-as-board-opens-investigation
0 replies
Techdamentals Nov 9, 5:09 AM
$JNJ grew worldwide sales 5.9% from a year earlier in its July to September 2026 quarter, to $25.40 billion from $23.99 billion. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator reads the fundamentals in plain English, from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. https://techdamentals.com/v3/JNJ?ref=st
0 replies
RockyTSTH Nov 8, 11:09 PM
OPTION WATCHLIST 11/8/26 $MU - Memory stocks having a strong pull back to support level at $650. Stock has a gap to fill from $760 to $790. High watch for reversal to the upside if $700 level breaks. $JNJ - Stock rejecting all time high area multiple times. Watching here for a breakout if all time highs break for a move towards $300. Stock is in a decent uptrend. $XOM - oil in a pull back post elections. Looking for puts below $163.50 for a move towards $155.80 support level. Stock has resistance at $170. Key level on watch if we retest. $AVGO - Stock at $290 support level on the daily. Stock breaking below channel support. High watch if we reverse and fill the upside gap from $314 to $325. Puts below $290 $NOC - War stocks on watch as democrats could push to stop the defense budget. Puts below $520 for a move towards $500 and lower.
1 replies
viggizags Nov 8, 10:21 PM
$BTC.X i said what what....i said what what Should have bought Woody Johnson coin instead $JNJ
0 replies
GTA_Terminal Nov 8, 7:23 PM
$JNJ Options Flow Leans to Calls: A Smart-Money Check on the Stock. Our options, insider and institutional data point to where a big move could come next. It's up about 1% from a week ago. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=JNJ&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=JNJ Read the full article for the full details: https://globaltradersacademy.com/articles/johnson-jnj-options-flow-turns-bullish-a-smart-money-check-on-the-stock?utm_source=stocktwits&utm_medium=social
0 replies
flychicken1991 Nov 8, 4:07 PM
$JNJ Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer. Impact: Positive (81%). The update provides modest upward valuation support for JNJ shares by strengthening the preliminary evidence behind a potential future prostate-cancer treatment; it does not establish a change in near-term earnings. Source and what to watch next: https://nimpact.tech/newsimpact/news/d12b952b4d6a3f06/jnj-johnson-johnson-reports-73-psa-response-rate-with-investigational-pa?utm_source=stocktwits&utm_medium=story_url
0 replies
focafoca99 Nov 7, 4:05 PM
$JNJ posted strong Phase 3 data for ICOTYDE, with 58% ACR20 response in psoriatic arthritis at week 16. https://www.rapidticker.com/news/jnj-johnson-johnson-announces-icotydeâ-icotrokinra-5950a6
0 replies